following a full submission considered under the end of life and orphan equivalent process:
encorafenib (Braftovi®) is accepted for use within NHSScotland.
Indication under review: In combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy.
Treatment with encorafenib plus cetuximab was associated with an improvement in overall survival when compared with investigator's choice of cetuximab plus differing chemotherapy in BRAF V600E mutated patients who had received first and second-line therapies for metastatic CRC.
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS / list prices that are equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Medicine details
- Medicine name:
- encorafenib (Braftovi)
- SMC ID:
- SMC2312
- Indication:
In combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy.
- Pharmaceutical company
- Pierre Fabre Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 10 May 2021